|
Treatment factors
|
NMA
|
MA
|
P-value
|
|---|
| |
(n = 349)
|
(n = 28)
| |
|---|
|
Curability of first surgery
| | |
0.353
|
|
Complete
|
96 (27.5%)
|
10 (35.7%)
| |
|
Incomplete
|
253 (72.5%)
|
18 (64.3%)
| |
|
Regimen of first chemotherapy
| | |
0.362
|
|
OXA-based
|
25 (7.1%)
|
3 (10.7%)
| |
|
IRI-based
|
18 (5.1%)
|
3 (10.7%)
| |
|
5-FU intravenously
|
43 (12.3%)
|
4 (14.2%)
| |
|
5-FU orally
|
36 (10.3%)
|
4 (14.2%)
| |
|
Additional resection
| | | |
|
Liver resection
|
75 (21.4%)
|
3 (10.7%)
|
0.228
|
|
Lung resection
|
10 (2.8%)
|
0 (0.0%)
|
1.000
|
- OXA, oxaliplatin; IRI, irinotecan; 5-FU, 5-fluolouracil; NMA, non-mucinous adenocarcinoma; MA, mucinous adenocarcinoma.
